Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3: Mevrometostat with Enzalutamide in mCSPC
NCT07028853Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of mevrometostat in prostate cancer (PCa), sponsored by Pfizer. Started Sep 2025; status: recruiting.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07028853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028853.